by Matt Agorist, The Free Thought Project:
The Pfizer COVID-19 vaccine clinical trial did not establish that the vaccine’s clinically consequential benefits outweighed its potential harms. Nor did the trial establish that vaccination reduced the overall burden of COVID-19-like symptoms, let alone that it reduced person-to-person transmission. More than five years later, revisiting the evidence is essential if we are to avoid repeating the same mistakes when the next public-health emergency arrives.
(Brownstone Institute) U.S. Health Secretary Robert F. Kennedy Jr.’s recent decision to terminate the COVID-19 emergency use authorization (EUA) declarations invites reconsideration of the evidence that launched this extraordinary regulatory chapter.
TRUTH LIVES on at https://sgtreport.tv/
The U.S. Food and Drug Administration’s (FDA) first EUA for a COVID-19 vaccine rested on its determination that the known and potential benefits of the Pfizer-BioNTech vaccine outweighed its known and potential risks. Yet the pivotal trial report did not bring those benefits and risks together within a common quantitative framework.
Better late than never: more than five years later, I did — and what I found was startling.
At first glance, the famous 95% efficacy against protocol-defined, laboratory-confirmed symptomatic COVID-19 — based on eight versus 162 cases in a trial that randomized 43,548 participants — seems highly promising.
But when this finding is considered alongside the broader set of participant-relevant outcomes (dispersed across the trial publication, its Supplementary Appendix, and the contemporaneous FDA review materials), the overall clinical picture looks markedly different.
Depending on the counting period used, the vaccine group had 2-8 fewer cases of severe COVID-19, whereas the safety data showed numerical excesses of 4-101 participants across clinically consequential adverse-event categories. These categories are not directly comparable, and some may overlap.
Read More @ TheFreeThoughtProject.com
